Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

TUSTIN, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient dosing has begun in its clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in breast cancer. The multicenter clinical trial is being conducted in the Republic of Georgia.

"We are now seeing good overall momentum in our bavituximab Phase II cancer program, and we are very pleased that our clinical colleagues in Europe have been so efficient in rapidly moving from protocol approval to trial initiation to patient dosing," said Steven W. King, president and CEO of Peregrine. "We are optimistic that all three bavituximab Phase II cancer trials will proceed well in the coming months and we look forward to reporting on our progress later this year."

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"Bavituximab represents a novel strategy for the treatment of cancer that has
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Susan Hedstrom, Executive Director of ... organization dedicated to supporting research to advance the ... today that FPWR has received the organization,s largest ... contributed $1 million in support of the ... "Our gift signifies our ...
(Date:5/21/2015)... May 21, 2015 uBiome, the ... a partnership with PicnicHealth, a healthcare company that ... diagnosed with Inflammatory Bowel Disease (IBD) will receive ... complementary uBiome research kit. Both companies were funded ... , For more information on this partnership ...
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains ... therapeutic imaging within a body lumen (open space). ... a low cost, single-use disposable illumination and camera module ... 18, 2013 and the patent approval was received on ... to customize the lighting and magnification of the endoscope ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 35 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3
... Diabetes will be a huge burden on ... improve healthcare coverage. Epinex Diagnostics , ... has developed a new diabetes monitoring device that ... healthcare system.(Photo: http://www.newscom.com/cgi-bin/prnh/20090310/LA81722 )The Epinex ...
... New statistics just released reveal that R&D investment in ... in 2008, an increase of 3 percent from 2007, ... Company, a San Francisco based global leader in life ... Equity, Merchant Banking and Media and the Washington DC-based ...
... the Official Beer of the 2010 Alltech FEI World Equestrian Games. ... ... Foundation today announced Kentucky Ale as the Official Beer of the ... , the title sponsor of the 2010 Games, owns the Alltech,s Lexington ...
Cached Biology Technology:Can Obama Plan Tackle Diabetes Crisis? Epinex Test Could Help 2R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 2R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008 3Kentucky Ale Will Be the Official Beer of the Alltech FEI World Equestrian Games 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... California, Berkeley, and the University of Maryland School of ... spring that happily eats plant material cellulose ... In fact, the microbe,s cellulose-digesting enzyme, called a ... Celsius (228 degrees Fahrenheit), significantly above the 100oC (212oF) ...
... tallest bird, the statuesque whooping crane ( Grus americana ), ... the Smithsonian,s National Zoological Park. An 11-year-old male whooping crane ... is now on exhibit in the nation,s capital. Whooping cranes ... United States. There are only eight other zoos in the ...
... The University of Colorado Boulder is involved with five ... may lead to new bone-loss treatments to an experiment ... thunders skyward July 8 on the last of NASA,s ... the global pharmaceutical companies Amgen and UCB, will test ...
Cached Biology News:Hot springs microbe yields record-breaking, heat-tolerant enzyme 2Hot springs microbe yields record-breaking, heat-tolerant enzyme 3National Zoo Welcomes Whooping Crane 2Final space shuttle to carry 5 CU-Boulder-built payloads 2Final space shuttle to carry 5 CU-Boulder-built payloads 3Final space shuttle to carry 5 CU-Boulder-built payloads 4
... Domain GenBank Accession Number : ... to residues 77-299 of human-PSD-95 (PDZ ... 0.075M NaCl containing 0.05% sodium azide ... on rat brain microsomal protein preparation ...
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... software has been designed and created in ... biologist friendly genotyping analysis tool. We incorporated ... groups into the software. Their main requirements ... and low acquisition cost. GeneMarker can ...
...
Biology Products: